Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
Medicare Payment Rates Announcement: Cardio Diagnostics Holdings, Inc. has received preliminary gapfill payment rates from CMS for its cardiovascular tests, Epi+Gen CHD™ at $350 and PrecisionCHD™ at $684.76, which are expected to be finalized later this year for claims starting January 1, 2025.
Impact on Cardiovascular Care: The company emphasizes that these tests will enhance access to advanced cardiovascular assessments for Medicare beneficiaries, addressing the high mortality rate from coronary heart disease among older Americans.
Trade with 70% Backtested Accuracy
Analyst Views on CDIO
About CDIO
About the author
Cardio Diagnostics Partners with India to Launch PrecisionCHD Coronary Test
- International Expansion: Cardio Diagnostics has partnered with Aimil Ltd. and Dr. Lal PathLabs Ltd. to introduce the PrecisionCHD coronary test in India, marking the company's first expansion outside the U.S. and targeting a market with rising heart disease rates.
- Technological Innovation: The PrecisionCHD test combines epigenetics, genetics, and AI to detect coronary heart disease at a molecular level from blood samples, addressing the urgent screening demand in urban areas of India where heart disease rates can reach as high as 13%, filling a gap left by traditional angiograms.
- Clinical Integration Progress: The partners have begun integrating the test into Dr. Lal PathLabs' clinical and lab network, with broader commercial deployment expected in 2026 under Indian clinical guidelines, enhancing access to advanced heart diagnostics.
- Executive Insights: Cardio Diagnostics CEO Dr. Meesha Dogan stated that the partnership advances equitable access to cutting-edge cardiovascular care, while Aimil's Executive Director Dr. Mallika Kapoor emphasized that this venture strengthens India's access to advanced heart diagnostics.
Cardio Diagnostics Launches PrecisionCHD Test in India with Aimil and Dr. Lal PathLabs
- Market Expansion: Cardio Diagnostics Holdings partners with Aimil Ltd. and Dr. Lal PathLabs Ltd. to launch the PrecisionCHD test, marking the company's first expansion outside the U.S. and official entry into the Indian market, which is crucial given the rising prevalence of cardiovascular diseases.
- Technological Innovation: The PrecisionCHD test can identify non-obstructive coronary heart disease, surpassing traditional angiography, thereby enabling doctors to provide personalized treatment plans that enhance the quality and effectiveness of healthcare services.
- Commercial Outlook: The test is expected to be commercially launched in 2026, with initial promotion through Dr. Lal PathLabs' laboratory and clinical network, a strategy that will facilitate rapid adaptation to Indian clinical and regulatory protocols, thereby increasing market acceptance.
- Market Reaction: Following the announcement, CDIO's stock surged 29.61% in pre-market trading, indicating a positive market response to this strategic partnership and reflecting investor confidence in the company's future growth potential.
Cardio Diagnostics Partners with Southdale YMCA to Enhance Heart Health Education for 14,000 Members
- Heart Health Collaboration: Cardio Diagnostics partners with Southdale YMCA to provide heart health education and advanced cardiovascular testing to over 14,000 members, enabling the community to better manage cardiovascular risk.
- Educational Event Scheduled: An in-person heart health education event is set for January 26, 2026, led by Chief Medical Officer Dr. Robert Philibert, offering practical guidance to reduce heart disease risk and enhance community health awareness.
- Heart Health Fair: The Southdale YMCA will host a Heart Health Fair on February 25, 2026, providing access to heart health resources and Cardio Diagnostics' clinical tests, promoting community engagement in heart health.
- Access to Advanced Testing: Members will benefit from discounted rates on Epi+Gen CHD™ and PrecisionCHD™, two clinically validated tests that assess heart disease risk through simple blood draws, facilitating broader heart disease prevention and management efforts.
Cardio Diagnostics Holdings, Inc. to Showcase Data Highlighting PrecisionCHD's Capability to Identify INOCA and MINOCA at the American Heart Association Scientific Sessions
Underdiagnosed Heart Conditions: Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are significant yet often undetected forms of heart disease, affecting a large number of patients, particularly women.
PrecisionCHD Test Presentation: Cardio Diagnostics will present new data at the AHA Scientific Sessions showcasing how their PrecisionCHD test, which utilizes epigenetic biomarkers, can effectively detect INOCA and MINOCA, providing a noninvasive diagnostic tool.
Research Findings: A study conducted with the University of Iowa demonstrated that DNA methylation markers in the PrecisionCHD test can sensitively and specifically identify INOCA presentations, offering personalized insights for patient care.
Advancing Cardiovascular Medicine: Cardio Diagnostics aims to revolutionize cardiovascular diagnostics through their AI-driven technology, making detection and management of heart disease more accessible and tailored to individual patient needs, especially for underserved populations.
Cardio Diagnostics Holdings, Inc. Teams Up with YMCA of East Tennessee to Provide Heart Health Education and Advanced Testing for the Local Community
Partnership Announcement: Cardio Diagnostics is partnering with the YMCA of East Tennessee to offer a customized program for its members, which includes educational sessions called "Wisdom Wednesdays" and discounted access to AI-powered cardiovascular tests.
Heart Disease Statistics: Heart disease is the leading cause of death in the U.S., with Tennessee having a notably high cardiovascular mortality rate, highlighting the importance of early detection and prevention initiatives.
Educational Initiatives: The program will feature six educational sessions starting in November 2025, focusing on coronary heart disease prevention and proactive heart health management.
Community Access: The collaboration aims to extend cardiovascular testing and educational resources beyond YMCA members to the entire East Tennessee community, promoting heart health awareness and proactive measures.
Cardio Diagnostics Holdings, Inc. Grows Provider Network with Addition of 15 New Organizations Nationwide
Expansion of Partnerships: Cardio Diagnostics has partnered with 15 new provider organizations across the U.S., showcasing the growing adoption of their AI-driven precision cardiovascular medicine tests, Epi+Gen CHD™ and PrecisionCHD™.
Diverse Care Models: The new partnerships span various medical specialties and care models, including concierge, functional medicine, and primary care practices, emphasizing personalized and preventive healthcare approaches.
Innovative Testing Technology: The integration of Epi+Gen CHD™ and PrecisionCHD™ allows providers to gain actionable insights into coronary heart disease and heart attack risk, enhancing patient care and treatment plans.
Mission for Accessibility: Cardio Diagnostics aims to make precision cardiovascular medicine more accessible, addressing the rising prevalence of cardiovascular disease and improving early detection and management across diverse patient populations.
Cardio Diagnostics Partners with India to Launch PrecisionCHD Coronary Test
- International Expansion: Cardio Diagnostics has partnered with Aimil Ltd. and Dr. Lal PathLabs Ltd. to introduce the PrecisionCHD coronary test in India, marking the company's first expansion outside the U.S. and targeting a market with rising heart disease rates.
- Technological Innovation: The PrecisionCHD test combines epigenetics, genetics, and AI to detect coronary heart disease at a molecular level from blood samples, addressing the urgent screening demand in urban areas of India where heart disease rates can reach as high as 13%, filling a gap left by traditional angiograms.
- Clinical Integration Progress: The partners have begun integrating the test into Dr. Lal PathLabs' clinical and lab network, with broader commercial deployment expected in 2026 under Indian clinical guidelines, enhancing access to advanced heart diagnostics.
- Executive Insights: Cardio Diagnostics CEO Dr. Meesha Dogan stated that the partnership advances equitable access to cutting-edge cardiovascular care, while Aimil's Executive Director Dr. Mallika Kapoor emphasized that this venture strengthens India's access to advanced heart diagnostics.
Cardio Diagnostics Launches PrecisionCHD Test in India with Aimil and Dr. Lal PathLabs
- Market Expansion: Cardio Diagnostics Holdings partners with Aimil Ltd. and Dr. Lal PathLabs Ltd. to launch the PrecisionCHD test, marking the company's first expansion outside the U.S. and official entry into the Indian market, which is crucial given the rising prevalence of cardiovascular diseases.
- Technological Innovation: The PrecisionCHD test can identify non-obstructive coronary heart disease, surpassing traditional angiography, thereby enabling doctors to provide personalized treatment plans that enhance the quality and effectiveness of healthcare services.
- Commercial Outlook: The test is expected to be commercially launched in 2026, with initial promotion through Dr. Lal PathLabs' laboratory and clinical network, a strategy that will facilitate rapid adaptation to Indian clinical and regulatory protocols, thereby increasing market acceptance.
- Market Reaction: Following the announcement, CDIO's stock surged 29.61% in pre-market trading, indicating a positive market response to this strategic partnership and reflecting investor confidence in the company's future growth potential.
Cardio Diagnostics Partners with Southdale YMCA to Enhance Heart Health Education for 14,000 Members
- Heart Health Collaboration: Cardio Diagnostics partners with Southdale YMCA to provide heart health education and advanced cardiovascular testing to over 14,000 members, enabling the community to better manage cardiovascular risk.
- Educational Event Scheduled: An in-person heart health education event is set for January 26, 2026, led by Chief Medical Officer Dr. Robert Philibert, offering practical guidance to reduce heart disease risk and enhance community health awareness.
- Heart Health Fair: The Southdale YMCA will host a Heart Health Fair on February 25, 2026, providing access to heart health resources and Cardio Diagnostics' clinical tests, promoting community engagement in heart health.
- Access to Advanced Testing: Members will benefit from discounted rates on Epi+Gen CHD™ and PrecisionCHD™, two clinically validated tests that assess heart disease risk through simple blood draws, facilitating broader heart disease prevention and management efforts.
Cardio Diagnostics Holdings, Inc. to Showcase Data Highlighting PrecisionCHD's Capability to Identify INOCA and MINOCA at the American Heart Association Scientific Sessions
Underdiagnosed Heart Conditions: Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are significant yet often undetected forms of heart disease, affecting a large number of patients, particularly women.
PrecisionCHD Test Presentation: Cardio Diagnostics will present new data at the AHA Scientific Sessions showcasing how their PrecisionCHD test, which utilizes epigenetic biomarkers, can effectively detect INOCA and MINOCA, providing a noninvasive diagnostic tool.
Research Findings: A study conducted with the University of Iowa demonstrated that DNA methylation markers in the PrecisionCHD test can sensitively and specifically identify INOCA presentations, offering personalized insights for patient care.
Advancing Cardiovascular Medicine: Cardio Diagnostics aims to revolutionize cardiovascular diagnostics through their AI-driven technology, making detection and management of heart disease more accessible and tailored to individual patient needs, especially for underserved populations.
Cardio Diagnostics Holdings, Inc. Teams Up with YMCA of East Tennessee to Provide Heart Health Education and Advanced Testing for the Local Community
Partnership Announcement: Cardio Diagnostics is partnering with the YMCA of East Tennessee to offer a customized program for its members, which includes educational sessions called "Wisdom Wednesdays" and discounted access to AI-powered cardiovascular tests.
Heart Disease Statistics: Heart disease is the leading cause of death in the U.S., with Tennessee having a notably high cardiovascular mortality rate, highlighting the importance of early detection and prevention initiatives.
Educational Initiatives: The program will feature six educational sessions starting in November 2025, focusing on coronary heart disease prevention and proactive heart health management.
Community Access: The collaboration aims to extend cardiovascular testing and educational resources beyond YMCA members to the entire East Tennessee community, promoting heart health awareness and proactive measures.
Cardio Diagnostics Holdings, Inc. Grows Provider Network with Addition of 15 New Organizations Nationwide
Expansion of Partnerships: Cardio Diagnostics has partnered with 15 new provider organizations across the U.S., showcasing the growing adoption of their AI-driven precision cardiovascular medicine tests, Epi+Gen CHD™ and PrecisionCHD™.
Diverse Care Models: The new partnerships span various medical specialties and care models, including concierge, functional medicine, and primary care practices, emphasizing personalized and preventive healthcare approaches.
Innovative Testing Technology: The integration of Epi+Gen CHD™ and PrecisionCHD™ allows providers to gain actionable insights into coronary heart disease and heart attack risk, enhancing patient care and treatment plans.
Mission for Accessibility: Cardio Diagnostics aims to make precision cardiovascular medicine more accessible, addressing the rising prevalence of cardiovascular disease and improving early detection and management across diverse patient populations.
